Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Gastrointestinal Cancer
Solutions
Online Inquiry

Gastrointestinal Cancer

Gastrointestinal (GI) cancers have the highest incidence and are the second leading cause of cancer deaths in the United States (after lung cancer). At Alfa Cytology, our team of seasoned biological experts has dedicated themselves to unraveling the intricate mechanisms underlying gastrointestinal cancer development and progression.

Introduction to Gastrointestinal Cancer

Gastrointestinal (GI) cancers, encompassing a diverse range of malignancies affecting the digestive system, pose a significant global health challenge. These complex and often aggressive diseases, which include cancers of the esophagus, stomach, small intestine, colon, rectum, and liver, account for a substantial proportion of cancer-related morbidity and mortality worldwide. The heterogeneity of GI cancers, marked by their varied etiologies, and molecular profiles, has long hindered the development of comprehensive treatment strategies.

Cancer site Estimated new cases Estimated deaths
Both sexes Male Female Both sexes Male Female
Digestive system 353,820 197,390 156,430 174,320 100,310 74,010
Esophagus 22,370 17,690 4,680 16,130 12,880 3,250
Stomach 26,890 16,160 10,730 10,880 6,490 4,390
Small intestine 12,440 6730 5,710 2,090 1,150 940
Colon & rectum 152,810 81,540 71,270 53,010 28,700 24,310
Colon 106,590 54,210 52,380
Rectum 46,220 27,330 18,890
Anus, anal canal, & anorectum 10,540 3360 7,180 2,190 1,000 1,190
Liver & intrahepatic bile duct 41,630 28,000 13,630 29,840 19,120 10,720
Gallbladder & other biliary 12,350 5,900 6,450 4,530 1,950 2,580
Pancreas 66,440 34,530 31,910 51,750 27,270 24,480
Other digestive organs 8,350 3,480 4,870 3,900 1,750 2,150

The gastrointestinal cancer treatment market is poised for substantial growth, driven by the rising incidence of GI cancers, the unmet clinical needs, and the relentless pursuit of more effective and personalized therapeutic solutions. According to industry analysts, the global GI cancer treatment market is projected to reach over $70 billion by 2028, expanding at a robust CAGR of 8.2% during the forecast period. The complex and multifaceted nature of GI cancers, coupled with the limitations of existing treatment modalities, has fueled the demand for innovative approaches that can overcome drug resistance and enhance quality of life.

Our Services

This surge in market size underscores the increasing demand for effective and innovative therapy solutions for gastrointestinal cancer. Committed to staying at the forefront of the rapidly evolving field of gastrointestinal cancer research, Alfa Cytology continuously invests in the development of innovative technologies and the expansion of its service offerings.

Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our preclinical services encompass a wide range of capabilities, including cell line development, high-throughput screening, pharmacokinetic and pharmacodynamic evaluations, and advanced animal models. For more information about our gastrointestinal cancer research services and how we can support your drug development initiatives, please don't hesitate to contact us.

For research use only.